A primer on the mechanics of P-glycoprotein the multidrug transporter

Pharmacological Research

Volumn 55, Issue 1, 2007, Pages 1-15

  Hennessy, M ^a   Spiers, J P ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

ABC transporter; Drug transport; Multidrug resistance; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALDOSTERONE; AMPRENAVIR; COLCHICINE; CYCLOSPORIN A; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIGOXIN; DOMPERIDONE; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; INDINAVIR; LOPERAMIDE; MEVINOLIN; MIFEPRISTONE; NELFINAVIR; OC 144 09; ONDANSETRON; PACLITAXEL; QUINIDINE; RITONAVIR; SAQUINAVIR; TACROLIMUS; TARIQUIDAR; TENIPOSIDE; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCRISTINE; ZOSUQUIDAR;

ALPHA HELIX; AMINO ACID SEQUENCE; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PREDICTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HYDROPHOBICITY; IMAGE ANALYSIS; MULTIDRUG RESISTANCE; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; PROTEIN VARIANT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURAL HOMOLOGY;

ADENOSINE TRIPHOSPHATASES; ANIMALS; DRUG RESISTANCE, MULTIPLE; HUMANS; P-GLYCOPROTEIN; PROTEIN BINDING;

EID: 33846215616     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.10.007     Document Type: Review

References (200)

1. Higgins C.F. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8 (1992) 67-113
2. Doige C.A., and Ames G.F.L. ATP-dependent transport systems in bacteria and humans: relevance to cystic fibrosis and multidrug resistance. Annu Rev Microbiol 47 (1993) 291-319
3. Dean M., Hamon Y., and Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42 (2001) 1007-1017
4. Callen D.F., Baker E., Simmers R.N., Seshadri R., and Roninson I.B. Localisation of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet 77 (1987) 142-144
5. Chin J.E., Soffir R., Noonan K.E., Choi K., and Roninson I.B. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 9 (1989) 3808-3820
6. Ruetz S., and Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77 (1994) 1071-1081
7. Smit J.J.M., Schinkel A.H., Oude Elferink R.P., Groen A.K., Wagenaar E., van Deemter L., et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absences of phospholipid from bile and to liver disease. Cell 75 (1993) 451-462
8. Smith A.J., van Helvoort A., van Meer G., Szabo K., Welker E., Szakacs G., et al. MDR3 glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 275 (2000) 23530-23539
9. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455 (1976) 152-162
10. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
11. van Veen H.W., Margolles A., Muller M., Higgins C.F., and Konings W.N. The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J 19 (2000) 2503-2514
12. Loo T.W., and Clarke D.M. Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein. Biochem Cell Biol 77 (1999) 11-23
13. Schinkel A.H., Kemp S., Dolle M., Rudenko G., and Wagenaar E. N-glycosylation and deletion mutants of the human MDR-1 P-glycoprotein. J Biol Chem 268 (1993) 7474-7481
14. Higgins C.F., Hiles I.D., Salmond G.P.C., Gill D.R., Downie J.A., Evans I.J., et al. A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature 323 (1986) 448-450
15. Hyde S.C., Emsley P., Hartshorn M.J., Mimmack M.M., Gileadi U., Pearce S.R., et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346 (1990) 362-365
16. Juranka P.F., Zastawny R.L., and Ling V. P-glycoprotein: multi-drug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3 (1989) 2583-2592
17. Loo T.W., and Clarke D.M. Membrane topology of a cysteine-less mutant of human P-glycoprotein. J Biol Chem 270 (1995) 843-848
18. Kast C., Canfield V., Levenson R., and Gros P. Membrane topology of P-glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3. Biochemistry 34 (1995) 4402-4411
19. Walker J.E., Saraste M., Runswick M.J., and Gay N.J. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1 (1982) 945-951
20. Linton K.J., and Higgins C.F. The Escherichia coli ATP-binding cassette (ABC) proteins. Mol Microbiol 28 (1998) 5-13
21. Gottesman M.M., Pastan I., and Ambudkar S.V. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6 (1996) 610-617
22. Kim I.W., Peng X.H., Sauna Z.E., FitzGerald P.C., Xia D., Muller M., et al. The conserved tyrosine residues 401 and 1044 in ATP sites of human P-glycoprotein are critical for ATP binding and hydrolysis: evidence for a conserved subdomain, the A-loop in the ATP-binding cassette. Biochemistry 45 (2006) 7605-7616
23. Loo T.W., Bartlett M.C., and Clarke D.M. The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing Walker A sequence. J Biol Chem 277 (2002) 41303-41306
24. Smith P.C., Karpowich N., Millen L., Moody J.E., Rosen J., Thomas P.J., et al. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 10 (2002) 139-149
25. Ambudkar S.V., Kim I.W., Xia D., and Sauna Z.E. The A-loop a conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett 580 (2006) 1049-1055
26. Hrycyna C.A., Ramachandra M., Germann U.A., Cheng P.W., Pastan I., and Gottesman M.M. Both ATP sites of human P-glycoprotein are essential but not symmetric. Biochemistry 38 (1999) 13887-13899
27. Azzaria M., Schurr E., and Gros P. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 9 (1989) 5289-5297
28. Urbatsch I.L., Julien M., Carrier I., Rousseau M.E., Cayrol R., and Gros P. Mutational analysis of conserved carboxylate residues in the nucleotide binding sites of P-glycoprotein. Biochemistry 39 (2000) 14138-14149
29. Rothnie A., Storm J., McMahon R., Taylor A., Kerr I.D., and Callaghan R. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. FEBS Lett 579 (2005) 3984-3990
30. Urbatsch I.L., Gimi K., Wilke-Mounts S., and Senior A.E. Investigation of the role of glutamine-471 and glutamine-1114 in the two catalytic sites of P-glycoprotein. Biochemistry 39 (2000) 11921-11927
31. Sonveaux N., Shapiro A.B., Goormaghtigh E., Ling V., and Ruysschaert J.-M. Secondary and tertiary structure changes of reconstituted P-glycoprotein. A fourier transform attenuated total reflection infrared spectroscopy analysis. J Biol Chem 271 (1996) 24617-24624
32. Dong M., Ladaviere L., Penin F., Deleage G., and Baggetto L.G. Secondary structure of P-glycoprotein investigated by circular dichroism and amino acid sequence analysis. Biochim Biophys Acta 1371 (1998) 317-334
33. Loo T.W., and Clark D.P. Mutational analysis of the predicted first transmembrane segment of each homologous half of human P-glycoprotein suggests that they are symmetrically arranged in the membrane. J Biol Chem 271 (1996) 15414-15419
34. Loo T.W., and Clark D.P. Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J Biol Chem 271 (1996) 27482-27487
35. Loo T.W., and Clarke D.M. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim Biophys Acta 1461 (1999) 315-325
36. Stenham D.R., Campbell J.D., Sansom M.S.P., Higgins C.F., Kerr I.D., and Linton K.J. An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulphide cross-linking and homology modelling. FASEB J 17 (2003) 2287-2289
37. Loo T.W., Bartlett M.C., and Clarke D.M. Disulphide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. J Biol Chem 279 (2004) 7692-7697
38. Loo T.W., Bartlett M.C., and Clarke D.M. Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein. J Biol Chem 279 (2004) 18232-18238
39. Jones P.M., and George A.M. A new structural model for P-glycoprotein. J Membr Biol 166 (1998) 133-147
40. Pleban K., Kopp S., Csaszar E., Peer M., Hrebicek T., Rizzi A., et al. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: a combined photoaffinity labeling-protein homology modeling approach. Mol Pharmacol 67 (2005) 365-374
41. Rosenberg M.F., Callaghan R., Modok S., Higgins C.F., and Ford R.C. Three-dimensional structure of P-glycoprotein. The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 280 (2005) 2857-2862
42. Chang G., and Roth C.B. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293 (2001) 1793-1800
43. Reyes C.L., and Chang G. Structure of the ABC transporter MsbA in complex with ADP, vanadate and lipopolysaccharide. Science 308 (2005) 1028-1031
44. Rosenberg M.F., Callaghan R., Ford R.C., and Higgins C.F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272 (1997) 10685-10694
45. Rosenberg M.F., Velarde G., Ford R.C., Martin C., Berridge G., Kerr I.D., et al. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J 20 (2001) 5615-5625
46. Lee J.-Y., Urbatsch I.L., Senior A.E., and Wilkens S. Projection structure of P-glycoprotein by electron microscopy. Evidence for a closed conformation of the nucleotide binding domains. J Biol Chem 277 (2002) 40125-40131
47. Sharom F.J. The P-glycoprotein efflux pump: how does it transport drugs?. J Membr Biol 160 (1997) 161-175
48. van Veen H.W., Callaghan R., Soceneantu L., Sardini A., Konings W.N., and Higgins C.F. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature 391 (1998) 291-295
49. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., and Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268 (1993) 21493-21496
50. Raviv Y., Pollard H.B., Bruggemann E.P., Pastan I., and Gottesman M.M. Photosensitised labelling of a functional multidrug transporter in living drug-resistant tumour cells. J Biol Chem 265 (1990) 3975-3980
51. Loo T.W., and Clarke D.M. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 274 (1999) 24759-24765
52. Shapiro A.B., Fox K., Lam P., and Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 259 (1999) 841-850
53. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., and Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58 (2000) 624-632
54. Loo T.W., Bartlett M.C., and Clarke D.M. Methanethiosulphonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites. J Biol Chem 278 (2003) 50136-50141
55. Lugo M.R., and Sharom F.J. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. Biochemistry 44 (2005) 14020-14029
56. Dey S., Ramachandra M., Pastan I., Gottesman M.M., and Ambudkar S.V. Evidence for two non-identical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94 (1997) 10594-10599
57. Ayesh S., Shao Y.-M., and Stein W.D. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 316 (1996) 8-18
58. 3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 49 (1995) 1851-1861
59. Borgnia M.J., Eytan G.D., and Assarak Y.G. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271 (1996) 3163-3171
60. Wang R.B., Kuo C.L., Lien L.L., and Lien E.J. Structure-activity relationship: analysis of P-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28 (2003) 203-228
61. Morris D.I., Greenberger L.M., Bruggemann E.P., Cardarelli C., Gottesman M.M., Pastan I., et al. Localisation of the forskolin labelling sites to both halves of P-glycoprotein: similarity of the sites labelled by forskolin and prazosin. Mol Pharmacol 46 (1994) 329-337
62. Bruggemann E.P., Currier S.J., Gottesman M.M., and Pastan I. Characterisation of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 267 (1992) 21020-21026
63. Germann U.A. P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A (1996) 927-944
64. Loo T.W., and Clarke D.M. Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J Biol Chem 272 (1997) 31945-31948
65. Loo T.W., and Clarke D.M. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analogue of verapamil, MTS-verapamil. J Biol Chem 276 (2001) 14972-14979
66. Loo T.W., Bartlett M.C., and Clarke D.M. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem J 396 (2006) 537-545
67. Loo T.W., and Clarke D.M. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277 (2002) 44332-44338
68. Ecker G.F., Csaszar E., Kopp S., Plagens B., Holzer W., Ernst W., et al. Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Mol Pharmacol 61 (2002) 637-648
69. Isenberg B., Thole H., Tummler B., and Demmer A. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. Eur J Biochem 268 (2001) 2629-2634
70. Peer M., Csaszar E., Vorlaufer E., Kopp S., and Chiba P. Photoaffinity labeling of P-glycoprotein. Mini Rev Med Chem 5 (2005) 165-172
71. Frelet A., and Klein M. Insight in eukaryotic ABC transporter function by mutation analysis. FEBS Lett 580 (2006) 1064-1084
72. Schilling R.A., Venter H., Velamakanni S., Bapna A., Woebking B., Shahi S., et al. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 27 (2006) 195-203
73. Kajiji S., Talbot F., Grizzuti K., Van Dyke-Phillips V., Agresti M., Safa A.R., et al. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry 32 (1993) 4185-4194
74. Loo T.W., and Clark D.P. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 268 (1993) 19965-19972
75. Loo T.W., and Clarke D.M. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem 276 (2001) 36877-36880
76. Loo T.W., Bartlett M.C., and Clarke D.M. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium. Biochemistry 43 (2004) 12081-12089
77. Loo T.W., and Clarke D.M. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"?. Biochem Biophys Res Commun 329 (2005) 419-422
78. Chang G., and Roth C.B. Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293 (2001) 1793-1800
79. Loo T.W., Bartlett M.C., and Clarke D.M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J Biol Chem 278 (2003) 13603-13606
80. Omote H., and Al-Shawi M.K. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J 90 (2006) 4046-4059
81. Shapiro A.B., and Ling V. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 269 (1994) 3745-3754
82. Sharom F.J., Yu X., Chu J.W.K., and Doige C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem J 308 (1995) 381-390
83. Urbatsch I.L., Al-Shawi M.K., and Senior A.E. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 33 (1994) 7069-7076
84. Al-Shawi M.K., Polar M.K., Omote H., and Figler R.A. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 278 (2003) 52629-52640
85. Loo T.W., Bartlett M.C., and Clarke D.M. Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site. J Biol Chem 278 (2003) 20449-20452
86. Senior A.E., Al-Shawi M.K., and Urbatsch I.L. The catalytic cycle of P-glycoprotein. FEBS Lett 377 (1995) 285-289
87. Martin C., Berridge G., Higgins C.F., and Callaghan R. The multidrug resistance reversal agents SR33557 modulates vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br J Pharmacol 122 (1997) 765-771
88. Ambudkar S.V., Lelong I.H., Zhang J., Cardarelli C.O., Gottesman M.M., and Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89 (1992) 8472-8476
89. Gottesman M.M., Pastan I., and Ambudkar S.V. P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6 (1996) 610-617
90. Doige C.A., Yu X.H., and Sharom F.J. Effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta 1146 (1993) 65-72
91. Kamau S.W., Kramer S.D., Gunthert M., and Wunderli-Allenapach H. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. In Vitro Cell Dev Biol Anim 41 (2005) 207-216
92. Loo T.W., and Clarke D.M. Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J Biol Chem 270 (1995) 22957-22961
93. Urbatsch I.L., Sankaran B., Bhagat S., and Senior A.E. Both P-glycoprotein nucleotide-binding sites are catalytically active. J Biol Chem 270 (1995) 26956-26961
94. Sharom F.J., Yu X., and Doige C.A. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 268 (1993) 24197-24202
95. Eytan G.D., Regev R., and Assaraf Y.G. Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. J Biol Chem 271 (1996) 3172-3178
96. Shapiro A.B., and Ling V. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein. Eur J Biochem 254 (1998) 189-193
97. Ambudkar S.V., Cardarelli C.O., Pashinsky I., and Stein W.D. Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem 272 (1997) 21260-21266
98. Delannoy S., Urbatsch I.L., Tombline G., Senior A.E., and Volberding P.A. Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry 44 (2005) 14010-14019
99. Urbatsch I.L., Sankaran B., Weber J., and Senior A.E. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 270 (1995) 19383-19390
100. Urbatsch I.L., Beaudet L., Carrier I., and Gros P. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Biochemistry 37 (1998) 4592-4602
101. Qu Q., Russell P.L., and Sharom F.J. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle. Biochemistry 42 (2003) 1170-1177
102. Rosenberg M.F., Kamis A.B., Callaghan R., Higgins C.F., and Ford R.C. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 278 (2003) 8294-8299
103. Loo T.W., Bartlett D.M., and Clarke D.M. ATP hydrolysis promotes interaction between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. Biochemistry 44 (2005) 10250-10258
104. Martin C., Higgins C.F., and Callaghan R. The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 40 (2001) 15733-15742
105. Mimura C.S., Holbrook S.R., and Ames G.F. Structural model of the nucleotide-binding conserved component of periplasmic permeases. Proc Natl Acad Sci USA 88 (1991) 84-88
106. Loo T.W., and Clarke D.M. Cross-linking of human multidrug resistance P-glycoprotein by the substrate, Tris-(2-maleimidoethyl) amine, is altered by ATP hydrolysis. Evidence for rotation of a transmembrane helix. J Biol Chem 276 (2001) 31800-31805
107. Ruth A., Stein W.D., Rose E., and Roninson I.B. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein. Biochemistry 40 (2001) 4332-4339
108. Druley T.E., Stein W.D., and Roninson I.B. Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity. Biochemistry 40 (2001) 4312-4322
109. Julien M., and Gros P. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity. Biochemistry 39 (2000) 4559-4568
110. Wang G.C., Pincheira R., and Zhang J.T. Dissection of drug-binding-induced conformational changes in P-glycoprotein. Eur J Biochem 255 (1998) 383-390
111. Liu R., and Sharom F.J. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains. Biochemistry 35 (1996) 11865-11873
112. Loo T.W., Bartlett M.C., and Clarke D.M. Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains. J Biol Chem 278 (2003) 1575-1578
113. Higgins C.F., and Linton K.J. The ATP switch model for ABC transporters. Nat Struct Mol Biol 11 (2005) 918-926
114. Linton KJ, Higgins CF. Structure and function of ABC transporters: the ATP switch provides flexible control. Pflug Arch Eur J Phys [Epub ahead of print].
115. Ambudkar S.V., Kim I.W., and Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharma Sci 27 (2006) 392-400
116. van Veen H.W., and Callaghan R. Substrate-binding sites in ABC transporters. In: Holland I.B., Cole S.P.C., Kuchler K., and Higgins C.F. (Eds). ABC proteins: from bacteria to man (2003), Elsevier, London 81-106
117. Krupka R.M. Uncoupled active transport mechanisms accounting for low selectivity in multidrug carriers: P-glycoprotein and SMR antiporters. J Membr Biol 172 (1999) 129-143
118. Zamora J.M., Pearce H.L., and Beck W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33 (1988) 454-462
119. Ueda K., Taguchi Y., and Morishima M. How does P-glycoprotein recognise its substrates?. Semin Cancer Biol 8 (1997) 151-159
120. Stouch T.R., and Gudmundsson O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev 54 (2002) 315-328
121. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251 (1998) 252-261
122. Seelig A. How does P-glycoprotein recognise its substrates?. Int J Clin Pharmacol Ther 36 (1998) 50-54
123. Seelig A., and Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12 (2000) 31-40
124. Cianchetta G., Singleton R.W., Zhang M., Wildgoose M., Giesing D., Fravolini A., et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J Med Chem 48 (2005) 2927-2935
125. Seelig A., Li Blatter X., and Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharmacol Ther 38 (2000) 111-121
126. Penzotti J.E., Lamb M.L., Evensen E., and Grootenhuis P.D.J. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45 (2002) 1737-1740
127. Wang Y.H., Li Y., Yang S.L., and Yang L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J Chem Inf Model 45 (2005) 750-757
128. Cabrera M.A., Gonzalez I., Fernandez C., Navarro C., and Bermejo M. A topological substructural approach for the prediction of P-glycoprotein substrates. J Pharm Sci 95 (2006) 589-606
129. Dantzig A.H., de Alwis D.P., and Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55 (2003) 133-150
130. Varma M.V.S., Ashokraj Y., Dey C.D., and Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48 (2003) 347-359
131. Chico I., Kang M.H., Bergan R., Abraham J., Bakke S., Meadows B., et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19 (2001) 832-842
132. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., et al. In vitro and in vivo reversal of P-glycoprotein mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61 (2001) 749-758
133. Newman M.J., Rodart J.C., Benbatoul K.D., Romano S.J., Zhang C., Krane S., et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60 (2000) 2964-2972
134. Dantzig A.H., Shepard R.L., Law K.L., Tabas L., Pratt S., Gillespie J.S., et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P450 activities. J Pharmacol Exp Ther 290 (1999) 854-890
135. Shepard R.L., Cao J., Starling J.J., and Dantzig A.H. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 103 (2003) 121-125
136. Leith C.P., Kopecky K.J., Chen I.M., Eijdems L., Slovak M.L., McConnell T.S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR-1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94 (1999) 1086-1099
137. Owen A., Chandler B., and Back D.J. The implications of P-glycoprotein in HIV: friend or foe?. Fundam Clin Pharmacol 19 (2005) 283-296
138. Ambudkar S.V. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
139. Sachs C.W., Safa A.R., Harrison S.D., and Fine R.L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 270 (1995) 26639-26648
140. Germann U.A., Chambers T.C., Ambudkar S.V., Licht T., Cardarelli C.O., Pastan I., et al. Characterisation of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 271 (1996) 1708-1716
141. Altenberg G.A., Vanoye C.G., Horton J.K., and Reuss L. Unidirectional fluxes of rhodamine 123 in multidrug-resistant cells: evidence against direct drug extrusion from the plasma membrane. Proc Natl Acad Sci USA 91 (1994) 4654-4657
142. Eytan G.D., Regev R., Oren R., and Assaraf Y.G. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 271 (1996) 12897-12902
143. Regev R., and Eytan G.D. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol 54 (1997) 1151-1158
144. De Graaf D., Sharma R.C., Mechetner E.B., Schimke R.T., and Roninson I.B. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 93 (1996) 1238-1242
145. Eytan G.D., Regev R., Oren G., Hurwitz C.D., and Assaraf Y.G. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 248 (1997) 104-112
146. Jones P.M., and George A.M. Symmetry and structure in P-glycoprotein and ABC transporters what goes around comes around. Eur J Biochem 267 (2000) 5298-5305
147. Bolhuis H., van Veen H.W., Molenaar D., Poolman B., Driessen A.J.M., and Konings W.N. Multidrug resistance in Lactococcus lactis: evidence for ATP-dependent drug extrusion from the inner leaflet of the cytoplasmic membrane. EMBO J 15 (1996) 4239-4245
148. Shapiro A.B., and Ling V. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 250 (1997) 122-129
149. Shapiro A.B., Corder A.B., and Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 250 (1997) 115-121
150. Shapiro A.B., and Ling V. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur J Biochem 254 (1998) 181-188
151. Chen Y., Pant A.C., and Simon S.M. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells. Cancer Res 61 (2001) 7763-7769
152. Higgins C.F., and Gottesman M.M. Is the multidrug transporter a flippase?. Trends Biochem Sci 17 (1992) 18-21
153. Hollo Z., Homolya L., Davis C.W., and Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1191 (1994) 384-388
154. Stein W.D., Cardarelli C., Pastan I., and Gottesman M.M. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 45 (1994) 763-772
155. Omote H., and Al-Shawi M.K. A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein. J Biol Chem 277 (2002) 45688-45694
156. Romsicki Y., and Sharom F.J. Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 40 (2001) 6937-6947
157. Eckford P.D.W., and Sharom F.J. The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J 389 (2005) 517-526
158. Chin K.V., Tanaka S., Darlington G., Pastan I., and Gottesman M.M. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265 (1990) 221-226
159. Miyazaki M., Kohno K., Uchiumi T., Tanimura H., Matsuo K., Nasu M., et al. Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem Biophys Res Commun 187 (1992) 677-684
160. Combates N.J., Kwon P.O., Rzepka R.W., and Cohen D. Involvement of the transcription factor NF-IL6 in phorbol ester induction of P-glycoprotein in U937 cells. Cell Growth Differ 8 (1997) 213-219
161. Chaudhary P.M., and Roninson I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85 (1993) 632-639
162. Chin K.V., Chauhan S.S., Pastan I., and Gottesman M.M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1 (1990) 361-365
163. Hu Z., Jin S., and Scotto K.W. Transcriptional activation of the MDR1 gene by UV irradiation. J Biol Chem 275 (2000) 2979-2985
164. Thottassery J.V., Zambett G.P., Arimeri K., Schuetz E.G., and Schuetz J.D. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 94 (1997) 11037-11042
165. Zastawny R.L., Salvino R., Chen J., Benchimol S., and Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8 (1993) 1529-1535
166. Wartenberg M., Hoffmann E., Schwindt H., Grunheck F., Petros J., Arnold J.R.S., et al. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumour spheroids. FEBS Lett 579 (2005) 4541-4549
167. Thorgeirsson S.S., Huber B.E., Sorrell S., Fojo A.T., Pastan I., and Gottesman M.M. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236 (1987) 1120-1122
168. Marino P.A., Gottesman M.M., and Pastan I. Regulation of the multidrug resistance gene in regenerating rat liver. Cell Growth Differ 1 (1990) 57-62
169. Abolhoda A., Wilson A.E., Ross H., Danenberg P.V., Burt M., and Scotto K.W. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5 (1999) 3352-3356
170. van Kalken C., Giaccone G., van der Valk P., Kuiper C.M., Hadisaputro M.M., Bosma S.A., et al. Multidrug resistance gene (P-glycoprotein) expression in the human foetus. Am J Pathol 141 (1992) 1063-1072
171. Nakayama M., Wada M., Harada T., Nagayama J., Kusaba H., Ohshima K., et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukaemias. Blood 92 (1998) 4296-4307
172. Vilsboa N.E., Galan A., Troyano A., de Blas E., and Aller P. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 275 (2000) 24970-24976
173. Cornwell M.M., and Smith D.E. Sp1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem 268 (1993) 19505-19511
174. Rohlff C., and Glazer R.I. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol 12 (1998) 383-386
175. Daschner P.J., Ciolino H.P., Plonzek C.A., and Yeh G.C. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Tr 53 (1999) 229-240
176. Combates N.J., Rzepka R.W., Chen Y.N., and Cohen D. NF-IL6 a member of the C/EBP family of transcription factors binds and trans-activates the human MDR1 gene promoter. J Biol Chem 269 (1994) 29715-29719
177. Jin S., and Scotto K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase/deacetylase is mediated by NF-Y. Mol Cell Biol 18 (1998) 4377-4384
178. McCoy C., Smith D.E., and Cornwell M.M. 12-O-Tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol Cell Biol 15 (1995) 6100-6108
179. Ohga T., Uchiumi T., Makino Y., Wada M., Kuwano M., and Kohno K. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273 (1998) 5997-6000
180. Ogretmen B., and Safa A.R. Identification and characterisation of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukaemia cell line. Biochemistry 39 (2000) 194-204
181. Ogretmen B., and Safa A.R. Negative regulation of MDR1 promoter activity in MCF-7, but not multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with a CAAT region. Biochemistry 38 (1999) 2189-2199
182. Li Z.H., Zhu Y.J., and Lit X.T. Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Lett 119 (1997) 177-184
183. Yague E., Armesilla A.L., Harrison G., Elliott J., Sardini A., Higgins C.F., et al. P-glycoprotein (MDR1) expression in leukaemic cells is regulated at two distinct steps, mRNA stabilisation and translational initiation. J Biol Chem 278 (2003) 10344-10352
184. Tchenio T., Havard M., Martinez L.A., and Dautry F. Heat shock-independent induction of multidrug resistance by heat shock factor 1. Mol Cell Biol 26 (2006) 580-591
185. Scotto K.W., and Johnson R.A. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol Interv 1 (2001) 117-125
186. Kuwano M., Uchiumi T., Hayakawa H., Ono M., Wada M., Izumi H., et al. The basic and clinical implications of ABC transporters, Y-box binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 94 (2003) 9-14
187. Madden M.J., Morrow C.S., Nakagawa M., Goldsmith M.E., Fairchild C.R., and Cowan K.H. Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem 268 (1993) 8290-8297
188. Scotto K.W. Transcriptional regulation of ABC drug transporters. Oncogene 22 (2003) 7496-7511
189. Synold T.W., Dussault I., and Forman B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7 (2001) 584-590
190. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. J Biol Chem 276 (2001) 14581-14587
191. Masuyama H., Hirsch-Ernst K.I., Mizutani H., Inoshita H., and Kudo T. The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol 172 (2001) 47-56
192. Masuyama H., Suwaki N., Tateishi Y., Nakatsukasa H., Segawa T., and Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol 19 (2005) 1170-1180
193. Burk O., Arnold K.A., Geick A., Tegude H., and Eichelbaum M. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression. Biol Chem 386 (2005) 503-513
194. Huff L.M., Wang Z., Iglesias A., Fojo T., and Lee J.S. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples. Cancer Res 65 (2005) 11694-11703
195. Mickley L.A., Spengler B.A., Knutsen T.A., Biedler J.L., and Fojo T. Gene rearrangement: a novel mechanism for MDR-1 gene activation. J Clin Invest 99 (1997) 1947-1957
196. Baker E.K., Johnstone R.W., Zalcberg J.R., and El-Osta A. Epigenetic changes to the MDR-1 locus in response to chemotherapeutic drugs. Oncogene 24 (2005) 8061-8075
197. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 (1993) 385-427
198. Callaghan R., Ford R.C., and Kerr I.D. The translocation mechanism of P-glycoprotein. FEBS Lett 580 (2006) 1056-1063
199. Johnstone R.W., Ruefli A.A., and Smyth M.J. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci 25 (2000) 1-6
200. Labialle S., Gayet L., Marthinet E., Rigal D., and Baggetto L.G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64 (2002) 943-948